RBC Capital Initiates Epizyme With Outperform

Analysts at RBC Capital initiated coverage on Epizyme Inc EPZM with a Outperform rating. The target price for Epizyme is set to $40. Epizyme shares have dropped 29.99 percent over the past 52 weeks, while the S&P 500 index has surged 5.01 percent in the same period. Epizyme shares fell 2.45 percent to close at $22.71 on Thursday.